Browsing tag:

European Commission


Bristol-Myers Squibb and Pfizer has announced that the European Commission has approved Apixaban (Eliquis) for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and the prevention of recurrent DVT and PE in adults. There is an estimated 600,000 people affected by DVT/PE each year in the U.S., and almost 100,000 of those people die[…]

Read More

On January 24, 2014 the European Commission announced their marketing authorization to both AstraZeneca and Bristol-Myers Squibb for Xigduo. As a powerful medication for type 2 diabetes, Xigduo is a combination of Dapagliflozin and Metformin Hydrochloride, and available in two dosages: 5mg/850mg and 5mg/1,000mg tablets, respectively. This dynamic duo of powerhouse anti-diabetic medications is designed[…]

Read More

Aflibercept, also known as brand name Eyelea, has been recently touted as a 2013 blockbuster drug. With sales of Aflibercept in the United States thought to have surpassed 1.3 billion dollars in the 2013 calendar year, the pharmaceutical community has been optimistically awaiting final year end data. Marketed by Regeneron in the U.S., Eyelea {Aflibercept}[…]

Read More

A clinical study spanning two years investigated the effects of the drug Bazedoxifene (Conbriza) at 10, 20 and 40 mg on postmenopausal women at risk for osteoporosis. The results showed positive indications for preventing bone loss and reducing bone turnover. What’s more is that the study demonstrated the drug’s safety profile and its use is[…]

Read More

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service